ETF · real data, updated daily
LABU · Direxion Daily S&P Biotech Bull 3x Shares
Over the last 11 years (2015-06 to 2026-09), $10,000 invested in LABU with dividends reinvested grew to $831, -19.71% a year, with a worst peak-to-trough fall of -98.66%. Past performance doesn't predict future results.
Growth of $10,000 · 2015-06 to 2026-09 · dividends reinvested
How LABU held up in past market crashes
LABU has been through 3 of the market crashes since 2000 in our data. Its deepest price fall was 88.9% in the 2022 bear market, when the S&P 500 fell 25.4%. Its price had not yet regained that high by the latest close (price only, not counting the dividends or interest it paid). No fund is safe from losses; past falls do not predict future ones.
| Crash | LABU deepest fall | S&P 500 (SPY) | Peak to bottom | Back to peak |
|---|---|---|---|---|
| 2018 fourth-quarter selloff | -74.0% | -20.2% | Sep 2018 to Dec 2018 | 23 months |
| 2020 COVID crash | -76.2% | -34.1% | Feb 2020 to Mar 2020 | 3 months |
| 2022 bear market | -88.9% | -25.4% | Jan 2022 to Jun 2022 | Not yet |
Price declines in the fund's listing currency, dividends not included, inside each crash's S&P 500 peak-to-bottom window. See how 50 popular ETFs compare in the crash study.
About LABU
Direxion Daily S&P Biotech Bull 3X Shares is a leveraged exchange-traded fund designed to provide daily investment results that correspond to three times the performance of the S&P Biotechnology Select Industry Index before fees and expenses. The fund focuses on U.S. biotechnology companies and uses derivatives, swap agreements, and related instruments to create amplified exposure to the sector. Its portfolio is built around biotech names across areas such as drug development, genomics, diagnostics, and life sciences, making it a specialized tool for tracking short-term moves in the biotechnology market. Direxion Daily S&P Biotech Bull 3X Shares is used by market participants seeking targeted exposure to biotechnology within a single fund structure.
Put LABU to the test
Every tool below opens prefilled with LABU: free, no account needed.
Backtest LABU →
Full history, any date range, benchmarks, drawdowns, rolling returns.
Would LABU survive 2008? →
What actually happened to it in the crisis: real drawdown and recovery.
Project it forward →
Monte Carlo simulation of where it could go from here.
Compare LABU vs VTI →
Head-to-head against the total US market.
Replay $100/mo into LABU →
Animated growth of steady monthly contributions.
Fundamentals →
Holdings-level financials where available.
Educational use only, not investment advice. Results are hypothetical.Read full disclaimer
This tool is for educational and informational purposes only and does not provide financial, investment, tax, legal, or accounting advice. Results are hypothetical and based on historical data and assumptions that may be inaccurate. Past performance does not guarantee future results. Consult a licensed professional before making investment decisions.